US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Super League Gaming Inc.

4.03

-0.3000-6.93%

Post-market: 3.97-0.0599-1.49%19:59 EDT

Volume:342.08K

Turnover:1.45M

Market Cap:8.05M

PE:-0.33

High:4.44

Open:4.28

Low:3.99

Close:4.33

52wk High:137.16

52wk Low:2.12

Shares:2.00M

Float Shares:1.65M

Volume Ratio:0.02

T/O Rate:20.78%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-12.3857

EPS(LYR):-40.4307

ROE:-503.98%

ROA:-64.67%

PB:0.62

PE(LYR):-0.10

Loading ...

Overview Company News Filings

Vor Bio Announces Publication of Interim Analysis of TELIGAN, a China Phase 3 Trial of Telitacicept in IgA Nephropathy, in The New England Journal of Medicine

Climb Bio to Present New Budoprutug Clinical Data at European Hematology Association (EHA) 2026 Congress

Super League Enterprise Inc expected to post a loss of $2.08 a share - Earnings Preview

Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates

Vor Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update

Press Release: Zenas BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Update

Super League Enterprise director Robert Kalutkiewicz files initial beneficial ownership statement

Climb Bio Reports First Quarter 2026 Financial Results and Provides Business Updates

Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results

Super League names Robert Kalutkiewicz to board as Mark Jung steps down

Super League closes acquisition of Misfits Ads Division from Misfits Gaming Group

LBL-047 Prioritized for Clinical Development in Sjögren's Disease, Systemic Lupus Erythematosus, and Dermatomyositis

Super League sets first-quarter 2026 earnings release, hosts results webinar

Press Release: Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 2026 Financial Results

INmune Bio and Anthony Nolan Announce Strategic Expansion of CORDStrom™ MSC Platform Collaboration to Target RDEB, Oncology, and Inflammatory Diseases

Fate Therapeutics Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of FT819

Climb Bio Hosts Budoprutug R&D Spotlight Event Highlighting Topline Subcutaneous Formulation Data, Broad B-Cell Mediated Disease Opportunity, and Upcoming Data Readouts

CRISPR Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results

Fate Therapeutics Announces Three Presentations at the 2026 ASGCT Annual Meeting Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases

Cabaletta Bio reports promising RESET-PV and RESET-SLE data

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/SLE/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"SLE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SLE\",,,,,undefined,":{"symbol":"SLE","market":"US","secType":"STK","nameCN":"Super League Gaming Inc.","latestPrice":4.03,"timestamp":1787342400000,"preClose":4.33,"halted":0,"volume":342082,"hourTrading":{"tag":"盘后","latestPrice":3.9701,"preClose":4.03,"latestTime":"19:59 EDT","volume":9923,"amount":39762.1622,"timestamp":1787356781233,"change":-0.0599,"changeRate":-0.014864,"amplitude":0.029429},"delay":0,"changeRate":-0.06928406466512697,"floatShares":1646352,"shares":1997600,"eps":-12.385672,"marketStatus":"Market Closed","change":-0.3,"latestTime":"08-21 16:00:00 EDT","open":4.28,"high":4.4362,"low":3.99,"amount":1446237.1755000001,"amplitude":0.103048,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-12.385672,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787558400000},"marketStatusCode":7,"adr":0,"listingDate":1551157200000,"exchange":"NASDAQ","adjPreClose":4.33,"preHourTrading":{"tag":"盘前","latestPrice":4.3,"preClose":4.33,"latestTime":"09:29 EDT","volume":20499,"amount":87961.885467,"timestamp":1787318983394,"change":-0.03,"changeRate":-0.006928,"amplitude":0.083072},"postHourTrading":{"tag":"盘后","latestPrice":3.9701,"preClose":4.03,"latestTime":"19:59 EDT","volume":9923,"amount":39762.1622,"timestamp":1787356781233,"change":-0.0599,"changeRate":-0.014864,"amplitude":0.029429},"volumeRatio":0.02282414046556692},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SLE\",,,,,undefined,":{"symbol":"SLE","floatShares":1646352,"roa":"-64.67%","roe":"-503.98%","lyrEps":-40.430703,"volumeRatio":0.02282414046556692,"shares":1997600,"dividePrice":0,"high":4.4362,"amplitude":0.103048,"preClose":4.33,"low":3.99,"week52Low":2.12,"pbRate":"0.62","psRate":"0.69","week52High":137.16,"institutionHeld":0,"latestPrice":4.03,"eps":-12.385672,"divideRate":0,"volume":342082,"delay":0,"ttmEps":-12.385672,"open":4.28,"prevYearClose":7.326,"prevWeekClose":2.27,"prevMonthClose":2.66,"prevQuarterClose":2.97,"fiveDayClose":2.27,"twentyDayClose":2.66,"sixtyDayClose":3.72},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SLE\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-14","symbol":"SLE","fiscalQuarterEnding":"2026/06","expectedEps":null,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1786680000000,"reportTimeType":"pre","actualEps":-2.7},{"market":"US","date":"2026-05-15","symbol":"SLE","fiscalQuarterEnding":"2026/03","expectedEps":-2.64,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1778817600000,"reportTimeType":"pre","actualEps":-1.77},{"market":"US","date":"2026-03-27","symbol":"SLE","fiscalQuarterEnding":"2025/12","expectedEps":-3.12,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1774584000000,"reportTimeType":"pre","actualEps":-9.44},{"market":"US","date":"2026-01-23","symbol":"SLE","defaultRemindTime":1769178600000,"type":"split","dateTimestamp":1769144400000,"forFactor":12,"toFactor":1,"ratio":12},{"market":"US","date":"2025-11-13","symbol":"SLE","fiscalQuarterEnding":"2025/09","expectedEps":-2.83,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1763010000000,"reportTimeType":"post","actualEps":-2.3}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SLE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SLE\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":4,"updateTime":1782792000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SLE\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SLE","date":"2026-08-21","current":-0.325376,"percent":0.342697,"low":-0.738945,"twenty":-0.347244,"median":-0.26748,"eighty":-0.210977,"high":-0.044016,"avg":-0.281117,"sd":0.1162,"marketCap":6506742},"quantilePoints":[{"date":"2023-09-15","current":-0.077235,"twenty":-0.086128,"median":-0.080205,"eighty":-0.078423,"marketCap":6401787},{"date":"2023-09-22","current":-0.075989,"twenty":-0.079611,"median":-0.075989,"eighty":-0.069678,"marketCap":6298532},{"date":"2023-09-29","current":-0.074744,"twenty":-0.077567,"median":-0.075367,"eighty":-0.07167,"marketCap":6195277},{"date":"2023-10-06","current":-0.072252,"twenty":-0.076986,"median":-0.074328,"eighty":-0.071255,"marketCap":5988768},{"date":"2023-10-13","current":-0.056058,"twenty":-0.075906,"median":-0.072252,"eighty":-0.068681,"marketCap":4646458},{"date":"2023-10-20","current":-0.059795,"twenty":-0.075491,"median":-0.072252,"eighty":-0.064944,"marketCap":4956222},{"date":"2023-10-27","current":-0.044846,"twenty":-0.075325,"median":-0.071006,"eighty":-0.062951,"marketCap":3717166},{"date":"2023-11-03","current":-0.051075,"twenty":-0.07491,"median":-0.068931,"eighty":-0.055726,"marketCap":4233439},{"date":"2023-11-10","current":-0.053151,"twenty":-0.074494,"median":-0.066439,"eighty":-0.051324,"marketCap":4405530},{"date":"2023-11-17","current":-0.15932,"twenty":-0.07491,"median":-0.066023,"eighty":-0.051324,"marketCap":5300404},{"date":"2023-11-24","current":-0.213857,"twenty":-0.076737,"median":-0.067685,"eighty":-0.052154,"marketCap":7114796},{"date":"2023-12-01","current":-0.221494,"twenty":-0.122932,"median":-0.069346,"eighty":-0.053317,"marketCap":7368896},{"date":"2023-12-08","current":-0.2024,"twenty":-0.203928,"median":-0.072252,"eighty":-0.053898,"marketCap":6733646},{"date":"2023-12-15","current":-0.235497,"twenty":-0.21182,"median":-0.072252,"eighty":-0.054563,"marketCap":7834746},{"date":"2023-12-22","current":-0.217675,"twenty":-0.215894,"median":-0.074536,"eighty":-0.054978,"marketCap":7241846},{"date":"2023-12-29","current":-0.203673,"twenty":-0.216403,"median":-0.075159,"eighty":-0.055227,"marketCap":6775996},{"date":"2024-01-05","current":-0.2024,"twenty":-0.216403,"median":-0.075782,"eighty":-0.055726,"marketCap":6733646},{"date":"2024-01-12","current":-0.210038,"twenty":-0.216403,"median":-0.07765,"eighty":-0.056058,"marketCap":6987746},{"date":"2024-01-19","current":-0.220221,"twenty":-0.217675,"median":-0.090076,"eighty":-0.057553,"marketCap":7326546},{"date":"2024-01-26","current":-0.238043,"twenty":-0.218439,"median":-0.176404,"eighty":-0.060459,"marketCap":7919446},{"date":"2024-02-02","current":-0.263515,"twenty":-0.222258,"median":-0.2024,"eighty":-0.062452,"marketCap":8766869},{"date":"2024-02-09","current":-0.288961,"twenty":-0.22404,"median":-0.203673,"eighty":-0.064279,"marketCap":9613445},{"date":"2024-02-16","current":-0.328423,"twenty":-0.227604,"median":-0.204946,"eighty":-0.06511,"marketCap":10926294},{"date":"2024-02-23","current":-0.31442,"twenty":-0.235497,"median":-0.207492,"eighty":-0.065774,"marketCap":10460445},{"date":"2024-03-01","current":-0.306782,"twenty":-0.258166,"median":-0.208765,"eighty":-0.066522,"marketCap":10206345},{"date":"2024-03-08","current":-0.254591,"twenty":-0.26656,"median":-0.210038,"eighty":-0.067186,"marketCap":8469996},{"date":"2024-03-15","current":-0.225313,"twenty":-0.263003,"median":-0.213857,"eighty":-0.068681,"marketCap":7495946},{"date":"2024-03-22","current":-0.349526,"twenty":-0.275749,"median":-0.21513,"eighty":-0.069346,"marketCap":11628396},{"date":"2024-03-28","current":-0.4417,"twenty":-0.283869,"median":-0.216403,"eighty":-0.069346,"marketCap":13396770},{"date":"2024-04-05","current":-0.367495,"twenty":-0.286708,"median":-0.217039,"eighty":-0.071006,"marketCap":11146112},{"date":"2024-04-12","current":-0.300356,"twenty":-0.297872,"median":-0.218948,"eighty":-0.072252,"marketCap":9109803},{"date":"2024-04-19","current":-0.288,"twenty":-0.297872,"median":-0.220857,"eighty":-0.072252,"marketCap":8735051},{"date":"2024-04-26","current":-0.293245,"twenty":-0.295326,"median":-0.222767,"eighty":-0.072252,"marketCap":8894120},{"date":"2024-05-03","current":-0.294239,"twenty":-0.295326,"median":-0.22404,"eighty":-0.072252,"marketCap":8924269},{"date":"2024-05-10","current":-0.276346,"twenty":-0.294239,"median":-0.22404,"eighty":-0.073498,"marketCap":8381577},{"date":"2024-05-17","current":-0.295605,"twenty":-0.295605,"median":-0.227222,"eighty":-0.074328,"marketCap":8381577},{"date":"2024-05-24","current":-0.265832,"twenty":-0.295326,"median":-0.232951,"eighty":-0.074744,"marketCap":7537390},{"date":"2024-05-31","current":-0.292406,"twenty":-0.294456,"median":-0.235497,"eighty":-0.075076,"marketCap":8290883},{"date":"2024-06-07","current":-0.271353,"twenty":-0.294239,"median":-0.238043,"eighty":-0.075491,"marketCap":7693940},{"date":"2024-06-14","current":-0.252339,"twenty":-0.293643,"median":-0.245044,"eighty":-0.075823,"marketCap":7154833},{"date":"2024-06-21","current":-0.201872,"twenty":-0.292909,"median":-0.238043,"eighty":-0.076487,"marketCap":5723866},{"date":"2024-06-28","current":-0.196825,"twenty":-0.292574,"median":-0.238043,"eighty":-0.076986,"marketCap":5580762},{"date":"2024-07-05","current":-0.214489,"twenty":-0.291076,"median":-0.236984,"eighty":-0.077484,"marketCap":6081608},{"date":"2024-07-12","current":-0.257386,"twenty":-0.29019,"median":-0.238043,"eighty":-0.079183,"marketCap":7297929},{"date":"2024-07-15","current":-0.26748,"twenty":-0.29019,"median":-0.238043,"eighty":-0.079694,"marketCap":7584122},{"date":"2024-08-02","current":-0.322994,"twenty":-0.29019,"median":-0.238043,"eighty":-0.080205,"marketCap":9158186},{"date":"2024-08-09","current":-0.280097,"twenty":-0.291452,"median":-0.25,"eighty":-0.090076,"marketCap":7941864},{"date":"2024-08-16","current":-0.331284,"twenty":-0.291452,"median":-0.254591,"eighty":-0.144836,"marketCap":7941864},{"date":"2024-08-23","current":-0.53758,"twenty":-0.294239,"median":-0.257262,"eighty":-0.15932,"marketCap":12887411},{"date":"2024-08-30","current":-0.506735,"twenty":-0.296227,"median":-0.259657,"eighty":-0.193489,"marketCap":12147969},{"date":"2024-09-06","current":-0.478094,"twenty":-0.298215,"median":-0.261996,"eighty":-0.196158,"marketCap":11461345},{"date":"2024-09-13","current":-0.387888,"twenty":-0.305764,"median":-0.26512,"eighty":-0.200267,"marketCap":9298829},{"date":"2024-09-20","current":-0.279367,"twenty":-0.307264,"median":-0.267321,"eighty":-0.201723,"marketCap":6697270},{"date":"2024-09-27","current":-0.280954,"twenty":-0.305764,"median":-0.2674,"eighty":-0.201872,"marketCap":6735311},{"date":"2024-10-04","current":-0.340548,"twenty":-0.30919,"median":-0.267958,"eighty":-0.202294,"marketCap":8163949},{"date":"2024-10-11","current":-0.449597,"twenty":-0.311325,"median":-0.268116,"eighty":-0.2024,"marketCap":10778189},{"date":"2024-10-18","current":-0.388813,"twenty":-0.315693,"median":-0.269014,"eighty":-0.203418,"marketCap":9321020},{"date":"2024-10-25","current":-0.405078,"twenty":-0.328743,"median":-0.270264,"eighty":-0.203673,"marketCap":9710936},{"date":"2024-10-31","current":-0.447393,"twenty":-0.331576,"median":-0.271783,"eighty":-0.204227,"marketCap":10725354},{"date":"2024-11-08","current":-0.410367,"twenty":-0.346526,"median":-0.273854,"eighty":-0.204806,"marketCap":9837739},{"date":"2024-11-15","current":-0.436374,"twenty":-0.369724,"median":-0.275294,"eighty":-0.204946,"marketCap":10461183},{"date":"2024-11-22","current":-0.261371,"twenty":-0.368039,"median":-0.276231,"eighty":-0.20571,"marketCap":6435212},{"date":"2024-11-29","current":-0.294604,"twenty":-0.364668,"median":-0.276346,"eighty":-0.206728,"marketCap":7253456},{"date":"2024-12-06","current":-0.323013,"twenty":-0.356067,"median":-0.277855,"eighty":-0.207492,"marketCap":7952897},{"date":"2024-12-13","current":-0.312281,"twenty":-0.347526,"median":-0.28005,"eighty":-0.208001,"marketCap":7688663},{"date":"2024-12-20","current":-0.321435,"twenty":-0.346138,"median":-0.280097,"eighty":-0.208765,"marketCap":7914039},{"date":"2024-12-27","current":-0.339269,"twenty":-0.34373,"median":-0.28052,"eighty":-0.20902,"marketCap":8353132},{"date":"2025-01-03","current":-0.336691,"twenty":-0.344526,"median":-0.281632,"eighty":-0.210038,"marketCap":8289664},{"date":"2025-01-10","current":-0.383512,"twenty":-0.351706,"median":-0.282822,"eighty":-0.210038,"marketCap":9442446},{"date":"2025-01-17","current":-0.309808,"twenty":-0.347717,"median":-0.284299,"eighty":-0.211096,"marketCap":7627786},{"date":"2025-01-24","current":-0.310545,"twenty":-0.347233,"median":-0.284972,"eighty":-0.212858,"marketCap":7645920},{"date":"2025-01-31","current":-0.354781,"twenty":-0.353001,"median":-0.285142,"eighty":-0.213857,"marketCap":8735057},{"date":"2025-02-07","current":-0.319937,"twenty":-0.350441,"median":-0.285388,"eighty":-0.213857,"marketCap":7877163},{"date":"2025-02-14","current":-0.31412,"twenty":-0.349224,"median":-0.286351,"eighty":-0.213857,"marketCap":7733942},{"date":"2025-02-21","current":-0.308303,"twenty":-0.349022,"median":-0.286674,"eighty":-0.21411,"marketCap":7590720},{"date":"2025-02-28","current":-0.232681,"twenty":-0.348999,"median":-0.28664,"eighty":-0.214489,"marketCap":5728846},{"date":"2025-03-07","current":-0.21936,"twenty":-0.348284,"median":-0.285948,"eighty":-0.214489,"marketCap":5400869},{"date":"2025-03-14","current":-0.209704,"twenty":-0.347244,"median":-0.285144,"eighty":-0.213941,"marketCap":5163122},{"date":"2025-03-21","current":-0.201444,"twenty":-0.347002,"median":-0.285098,"eighty":-0.212359,"marketCap":4959748},{"date":"2025-03-28","current":-0.230354,"twenty":-0.345822,"median":-0.284304,"eighty":-0.212359,"marketCap":5671557},{"date":"2025-04-04","current":-0.234475,"twenty":-0.342935,"median":-0.283459,"eighty":-0.210567,"marketCap":3900496},{"date":"2025-04-11","current":-0.236161,"twenty":-0.340036,"median":-0.28231,"eighty":-0.212359,"marketCap":3928533},{"date":"2025-04-17","current":-0.236161,"twenty":-0.338893,"median":-0.280718,"eighty":-0.213857,"marketCap":3928533},{"date":"2025-04-25","current":-0.369736,"twenty":-0.338893,"median":-0.280836,"eighty":-0.213857,"marketCap":6150554},{"date":"2025-05-02","current":-0.394848,"twenty":-0.347107,"median":-0.282596,"eighty":-0.213857,"marketCap":6568294},{"date":"2025-05-09","current":-0.347723,"twenty":-0.34901,"median":-0.284084,"eighty":-0.213899,"marketCap":5784365},{"date":"2025-05-16","current":-0.174182,"twenty":-0.348716,"median":-0.282596,"eighty":-0.211859,"marketCap":2897515},{"date":"2025-05-23","current":-0.187657,"twenty":-0.347631,"median":-0.280836,"eighty":-0.209762,"marketCap":2928392},{"date":"2025-05-30","current":-0.243307,"twenty":-0.347723,"median":-0.280836,"eighty":-0.209995,"marketCap":3796802},{"date":"2025-06-06","current":-0.252949,"twenty":-0.347265,"median":-0.280718,"eighty":-0.210038,"marketCap":3947265},{"date":"2025-06-13","current":-0.226363,"twenty":-0.347212,"median":-0.28021,"eighty":-0.210038,"marketCap":3532387},{"date":"2025-06-20","current":-0.204904,"twenty":-0.346791,"median":-0.280097,"eighty":-0.210029,"marketCap":3197521},{"date":"2025-06-27","current":-0.222294,"twenty":-0.344958,"median":-0.279367,"eighty":-0.209283,"marketCap":3468896},{"date":"2025-07-03","current":-0.240225,"twenty":-0.342139,"median":-0.277573,"eighty":-0.209588,"marketCap":3748716},{"date":"2025-07-11","current":-0.314762,"twenty":-0.339781,"median":-0.277296,"eighty":-0.209879,"marketCap":4911855},{"date":"2025-07-18","current":-0.242124,"twenty":-0.33814,"median":-0.276346,"eighty":-0.210021,"marketCap":3778350},{"date":"2025-07-25","current":-0.228831,"twenty":-0.337327,"median":-0.276269,"eighty":-0.210038,"marketCap":3570911},{"date":"2025-08-01","current":-0.243781,"twenty":-0.33696,"median":-0.274358,"eighty":-0.210831,"marketCap":3804205},{"date":"2025-08-08","current":-0.233576,"twenty":-0.336712,"median":-0.273838,"eighty":-0.212858,"marketCap":3644959},{"date":"2025-08-15","current":-0.231876,"twenty":-0.33606,"median":-0.271353,"eighty":-0.213354,"marketCap":3618418},{"date":"2025-08-22","current":-0.221928,"twenty":-0.335323,"median":-0.269787,"eighty":-0.212104,"marketCap":3535981},{"date":"2025-08-29","current":-0.23749,"twenty":-0.333566,"median":-0.269388,"eighty":-0.213354,"marketCap":3783930},{"date":"2025-09-05","current":-0.192157,"twenty":-0.332345,"median":-0.269014,"eighty":-0.213084,"marketCap":3061642},{"date":"2025-09-12","current":-0.207719,"twenty":-0.332042,"median":-0.268116,"eighty":-0.210012,"marketCap":3309592},{"date":"2025-09-19","current":-0.247639,"twenty":-0.331721,"median":-0.267958,"eighty":-0.20982,"marketCap":3945637},{"date":"2025-09-26","current":-0.362878,"twenty":-0.332345,"median":-0.267958,"eighty":-0.210012,"marketCap":5781732},{"date":"2025-10-03","current":-0.272683,"twenty":-0.334082,"median":-0.268394,"eighty":-0.210038,"marketCap":4344654},{"date":"2025-10-10","current":-0.24891,"twenty":-0.332345,"median":-0.268116,"eighty":-0.210567,"marketCap":3965889},{"date":"2025-10-17","current":-0.321134,"twenty":-0.33627,"median":-0.269014,"eighty":-0.211856,"marketCap":5116629},{"date":"2025-10-24","current":-0.188157,"twenty":-0.335429,"median":-0.268704,"eighty":-0.211856,"marketCap":2997912},{"date":"2025-10-31","current":-0.131167,"twenty":-0.334082,"median":-0.267958,"eighty":-0.20982,"marketCap":2089890},{"date":"2025-11-07","current":-0.105839,"twenty":-0.332345,"median":-0.267719,"eighty":-0.208727,"marketCap":1686325},{"date":"2025-11-14","current":-0.110362,"twenty":-0.332042,"median":-0.267321,"eighty":-0.207583,"marketCap":1758390},{"date":"2025-11-21","current":-0.081028,"twenty":-0.331721,"median":-0.26512,"eighty":-0.206427,"marketCap":1285354},{"date":"2025-11-28","current":-0.659255,"twenty":-0.334597,"median":-0.266863,"eighty":-0.206708,"marketCap":10457765},{"date":"2025-12-05","current":-0.720254,"twenty":-0.337177,"median":-0.26748,"eighty":-0.207472,"marketCap":11425396},{"date":"2025-12-12","current":-0.614194,"twenty":-0.34219,"median":-0.267958,"eighty":-0.207492,"marketCap":9742959},{"date":"2025-12-19","current":-0.474574,"twenty":-0.347254,"median":-0.268394,"eighty":-0.207537,"marketCap":7528174},{"date":"2025-12-26","current":-0.4608,"twenty":-0.349022,"median":-0.269014,"eighty":-0.207719,"marketCap":7309663},{"date":"2026-01-02","current":-0.447318,"twenty":-0.351152,"median":-0.26966,"eighty":-0.207719,"marketCap":7095801},{"date":"2026-01-09","current":-0.503223,"twenty":-0.354793,"median":-0.269873,"eighty":-0.208261,"marketCap":7982631},{"date":"2026-01-16","current":-0.526743,"twenty":-0.360917,"median":-0.271353,"eighty":-0.208641,"marketCap":8355727},{"date":"2026-01-23","current":-0.388481,"twenty":-0.368101,"median":-0.272683,"eighty":-0.20874,"marketCap":6162476},{"date":"2026-01-30","current":-0.377954,"twenty":-0.369864,"median":-0.273838,"eighty":-0.208765,"marketCap":5995491},{"date":"2026-02-06","current":-0.254616,"twenty":-0.369341,"median":-0.274166,"eighty":-0.209154,"marketCap":4038966},{"date":"2026-02-13","current":-0.250952,"twenty":-0.368944,"median":-0.274262,"eighty":-0.209588,"marketCap":3980851},{"date":"2026-02-20","current":-0.244846,"twenty":-0.368353,"median":-0.273838,"eighty":-0.20982,"marketCap":3883993},{"date":"2026-02-27","current":-0.219812,"twenty":-0.367557,"median":-0.272683,"eighty":-0.209529,"marketCap":3486877},{"date":"2026-03-06","current":-0.285756,"twenty":-0.365648,"median":-0.271783,"eighty":-0.20982,"marketCap":4532940},{"date":"2026-03-13","current":-0.266522,"twenty":-0.361898,"median":-0.272212,"eighty":-0.210012,"marketCap":4227838},{"date":"2026-03-20","current":-0.285756,"twenty":-0.360355,"median":-0.272267,"eighty":-0.210038,"marketCap":4532940},{"date":"2026-03-27","current":-0.254616,"twenty":-0.358486,"median":-0.271712,"eighty":-0.210567,"marketCap":4038966},{"date":"2026-04-02","current":-0.208821,"twenty":-0.355643,"median":-0.27114,"eighty":-0.210302,"marketCap":3312533},{"date":"2026-04-10","current":-0.260127,"twenty":-0.354839,"median":-0.269787,"eighty":-0.210302,"marketCap":5389056},{"date":"2026-04-17","current":-0.281981,"twenty":-0.354827,"median":-0.26986,"eighty":-0.211608,"marketCap":5841796},{"date":"2026-04-24","current":-0.268594,"twenty":-0.354771,"median":-0.270513,"eighty":-0.212842,"marketCap":5564456},{"date":"2026-05-01","current":-0.267882,"twenty":-0.354343,"median":-0.269886,"eighty":-0.213819,"marketCap":5549706},{"date":"2026-05-08","current":-0.295375,"twenty":-0.352599,"median":-0.271247,"eighty":-0.213857,"marketCap":6119281},{"date":"2026-05-15","current":-0.286915,"twenty":-0.351648,"median":-0.272111,"eighty":-0.213857,"marketCap":5944027},{"date":"2026-05-22","current":-0.634562,"twenty":-0.354827,"median":-0.272503,"eighty":-0.213857,"marketCap":13032642},{"date":"2026-05-29","current":-0.249501,"twenty":-0.354781,"median":-0.272503,"eighty":-0.213857,"marketCap":5124247},{"date":"2026-06-05","current":-0.248769,"twenty":-0.35473,"median":-0.272212,"eighty":-0.214067,"marketCap":5109220},{"date":"2026-06-12","current":-0.241452,"twenty":-0.352795,"median":-0.271911,"eighty":-0.214067,"marketCap":4958949},{"date":"2026-06-18","current":-0.230477,"twenty":-0.35201,"median":-0.271247,"eighty":-0.214405,"marketCap":4733542},{"date":"2026-06-26","current":-0.225356,"twenty":-0.351152,"median":-0.269886,"eighty":-0.214489,"marketCap":4628352},{"date":"2026-07-02","current":-0.229746,"twenty":-0.35011,"median":-0.269715,"eighty":-0.214549,"marketCap":4718515},{"date":"2026-07-10","current":-0.220234,"twenty":-0.349224,"median":-0.269201,"eighty":-0.214489,"marketCap":4523163},{"date":"2026-07-17","current":-0.207795,"twenty":-0.349022,"median":-0.268594,"eighty":-0.214067,"marketCap":4267702},{"date":"2026-07-24","current":-0.19682,"twenty":-0.348987,"median":-0.268161,"eighty":-0.213857,"marketCap":4042295},{"date":"2026-07-31","current":-0.20121,"twenty":-0.348468,"median":-0.267958,"eighty":-0.213493,"marketCap":4132458},{"date":"2026-08-07","current":-0.202674,"twenty":-0.34754,"median":-0.267882,"eighty":-0.210977,"marketCap":4162512},{"date":"2026-08-14","current":-0.245842,"twenty":-0.347244,"median":-0.2674,"eighty":-0.211398,"marketCap":5049112},{"date":"2026-08-21","current":-0.293824,"twenty":-0.347244,"median":-0.26748,"eighty":-0.210977,"marketCap":6506742}],"updateTime":1787489499394},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SLE\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2635171647","title":"Vor Bio Announces Publication of Interim Analysis of TELIGAN, a China Phase 3 Trial of Telitacicept in IgA Nephropathy, in The New England Journal of Medicine","url":"https://stock-news.laohu8.com/highlight/detail?id=2635171647","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635171647?lang=en_us&edition=fundamental","pubTime":"2026-05-14 20:30","pubTimestamp":1778761800,"startTime":"0","endTime":"0","summary":"Interim analysis demonstrated a 55.0% relative reduction in proteinuria versus placebo at 39 weeks with eGFR remaining stable through treatment Results further support the potential for telitacicept t","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/14/3294940/0/en/Vor-Bio-Announces-Publication-of-Interim-Analysis-of-TELIGAN-a-China-Phase-3-Trial-of-Telitacicept-in-IgA-Nephropathy-in-The-New-England-Journal-of-Medicine.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLE","RA","BK4077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635173719","title":"Climb Bio to Present New Budoprutug Clinical Data at European Hematology Association (EHA) 2026 Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2635173719","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635173719?lang=en_us&edition=fundamental","pubTime":"2026-05-14 19:00","pubTimestamp":1778756400,"startTime":"0","endTime":"0","summary":"WELLESLEY HILLS, Mass., May  14, 2026  (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, to","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/14/3294750/0/en/Climb-Bio-to-Present-New-Budoprutug-Clinical-Data-at-European-Hematology-Association-EHA-2026-Congress.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4077","SLE","EPV","BK4199","ITP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635621733","title":"Super League Enterprise Inc  expected to post a loss of $2.08 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2635621733","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635621733?lang=en_us&edition=fundamental","pubTime":"2026-05-13 22:21","pubTimestamp":1778682074,"startTime":"0","endTime":"0","summary":"Super League Enterprise Inc  expected to post a loss of $2.08 a share - Earnings Preview Super League Enterprise Inc SLE.OQ SLE.O is expected to  show a rise in quarterly revenue when it reports  resu","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nL8N41Q207:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4077","SLE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635782088","title":"Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2635782088","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635782088?lang=en_us&edition=fundamental","pubTime":"2026-05-13 20:30","pubTimestamp":1778675400,"startTime":"0","endTime":"0","summary":"RECLAIM – LN, a Phase 2 potentially registrational clinical trial of FT819 in patients with refractory moderate-to-severe systemic lupus erythematosus (SLE) with lupus nephritis, on schedule to initia","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/13/3293996/24675/en/Fate-Therapeutics-Reports-First-Quarter-2026-Financial-Results-and-Business-Updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4533","BK4139","LU2746668974.SGD","SG9999014567.USD","IE00BLSP4239.USD","LU0795875086.SGD","LU2125154935.USD","FATE","LU1868836591.USD","LU1894683348.USD","IE00BBT3K403.USD","LU2133065610.SGD","IIM","LU0912757837.SGD","LU2237443622.USD","SG9999014559.SGD","SLE","LU1920063259.USD","LU2125154778.USD","SITC","LU1670711123.USD","LU2347655156.SGD","BK4504","LU0545039389.USD","IE00B3PB1722.GBP","LU0882574139.USD","LU0949170772.SGD","BK4080","LU0098860793.USD","LU0289960550.SGD","LU1732799900.SGD","LU1868837136.USD","IE00BVYPNW00.USD","LU2237443465.HKD","LU0971096721.USD","CAR","LU1920062954.HKD","SG9999011175.SGD","BK4581","IND","LU0170899867.USD","LU1894683264.USD","RA","LU1221951046.USD","LU2506951875.HKD","LU0096364046.USD","KO","CMC","BK4559"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635782086","title":"Vor Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2635782086","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635782086?lang=en_us&edition=fundamental","pubTime":"2026-05-13 20:30","pubTimestamp":1778675400,"startTime":"0","endTime":"0","summary":"Enrollment on track for Phase 3 UPSTREAM MG trial of telitacicept in generalized myasthenia gravis patients with topline results anticipated in 1H27 Enrollment ongoing for Phase 3 UPSTREAM SjD of teli","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/13/3294002/0/en/Vor-Bio-Reports-First-Quarter-2026-Financial-Results-and-Provides-Corporate-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4077","RA","SLE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635200456","title":"Press Release: Zenas BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2635200456","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635200456?lang=en_us&edition=fundamental","pubTime":"2026-05-13 18:00","pubTimestamp":1778666400,"startTime":"0","endTime":"0","summary":"-- Obexelimab marketing applications for the treatment of IgG4-RD on-target for submission to the FDA this quarter and the EMA in H2 2026 based on the Phase 3 INDIGO IgG4-RD trial results --. -- Obexelimab Phase 3 INDIGO IgG4-RD trial results accepted for oral presentation at EULAR 2026 --. -- Obexelimab global Phase 2 SunStone SLE trial enrollment complete; topline results expected in Q4 2026 --. -- First subject dosed in Phase 1 trial of ZB021 ; initial clinical data expected by year-end --. -- Orelabrutinib global Phase 3 PriMroSe trial in patients with PPMS and global Phase 3 Monarch trial in patients with naSPMS ongoing --. -- Completed public offerings and entered into debt financing; cash runway extended into 2029 --. WALTHAM, Mass., May 13, 2026  -- Zenas BioPharma, Inc.  , a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases, today reported","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4215","MAA","BK4588","BK4077","BK4139","ZBIO","SLE","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633732453","title":"Super League Enterprise director Robert Kalutkiewicz files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2633732453","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633732453?lang=en_us&edition=fundamental","pubTime":"2026-05-08 19:43","pubTimestamp":1778240620,"startTime":"0","endTime":"0","summary":"Super League Enterprise filed an initial beneficial ownership statement naming Robert Kalutkiewicz as a director, dated May 6.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Super League Enterprise Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 08, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nNDL9ZBzpw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4077","SLE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633453731","title":"Climb Bio Reports First Quarter 2026 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2633453731","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633453731?lang=en_us&edition=fundamental","pubTime":"2026-05-07 19:00","pubTimestamp":1778151600,"startTime":"0","endTime":"0","summary":"Robust B-cell depletion observed with budoprutug subcutaneous formulation in healthy volunteers, supporting continued development CLYM116 modeling and initial Phase 1 safety data to be presented at ER","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/07/3289829/0/en/Climb-Bio-Reports-First-Quarter-2026-Financial-Results-and-Provides-Business-Updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ITP","SLE","PK","BK4181","PD","BK4077","BK4218","BK4199","LU1169589451.USD","LU1169590202.USD","BK4023"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633145383","title":"Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2633145383","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633145383?lang=en_us&edition=fundamental","pubTime":"2026-05-07 19:00","pubTimestamp":1778151600,"startTime":"0","endTime":"0","summary":"Initial clinical data in SLE and RA for CLN-978, a CD19 T cell engager, to be presented at the EULAR 2026 Congress in June; multi-dose regimen data in RA expected in Q3 2026 Zipalertinib NDA for relap","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/07/3289800/0/en/Cullinan-Therapeutics-Provides-Corporate-Update-and-Reports-First-Quarter-2026-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLE","BK4077","CGEM","BK4139","RA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633113571","title":"Super League names Robert Kalutkiewicz to board as Mark Jung steps down","url":"https://stock-news.laohu8.com/highlight/detail?id=2633113571","media":"Reuters","labels":["executive","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633113571?lang=en_us&edition=fundamental","pubTime":"2026-05-06 21:02","pubTimestamp":1778072538,"startTime":"0","endTime":"0","summary":"Super League named Robert Kalutkiewicz to board, effective today, as condition of closing acquisition of Misfits Ads Division.Kalutkiewicz serves as senior vice president of corporate development, strategy, strategic investments at E.W. Scripps.Justin Stefanovic joined management as senior vice president of business development and platform strategy, coming from senior vice president role at Misfits Gaming Group.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Super League Enterprise Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 06, 2026, and is solely responsible for the inform","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nNDL8FcbLN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SSP","BK4077","SLE","BK4125"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633135089","title":"Super League closes acquisition of Misfits Ads Division from Misfits Gaming Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2633135089","media":"Reuters","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633135089?lang=en_us&edition=fundamental","pubTime":"2026-05-06 21:02","pubTimestamp":1778072527,"startTime":"0","endTime":"0","summary":"Super League closed its acquisition of Misfits Gaming Group’s Misfits Ads Division, adding a programmatic advertising business and proprietary rewarded-video monetization technology.Contribution to financial results expected to begin in Q2, supporting a target of cash-based EBITDA profitability by year end.Deal expands scale in gaming advertising, targeting an under-monetized market where US gaming ad spend is near $10 billion versus more than $150 billion across social and streaming.Transaction includes a preferred commercial brand partnership with Misfits Gaming Group covering brand integrations across Roblox games reaching more than 100 million monthly active users.Board changes tied to closing include Robert Kalutkiewicz joining as a director, replacing Mark Jung; former Misfits executive Justin Stefanovic joined as SVP of business development and platform strategy.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT s","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nNDL3Fm7Lt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4547","LU1861559042.SGD","BK4554","IE0001KFT4U8.USD","BK4598","LU0786609619.USD","BK4588","BK4535","LU0348723411.USD","RBLU","BK4565","BK4085","LU2543165471.USD","LU2264538146.SGD","BK4585","BK4551","SLE","BK4077","RBLY","LU1861558580.USD","LU1988902786.USD","LU1064131342.USD","RBLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633972146","title":"LBL-047 Prioritized for Clinical Development in Sjögren's Disease, Systemic Lupus Erythematosus, and Dermatomyositis","url":"https://stock-news.laohu8.com/highlight/detail?id=2633972146","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633972146?lang=en_us&edition=fundamental","pubTime":"2026-05-06 10:57","pubTimestamp":1778036220,"startTime":"0","endTime":"0","summary":"NANJING, China, May  05, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (\"Leads Biolabs\"; Stock Code: 9887.HK) today announced that its partner, Dianthus Therapeutics, Inc. (“Dianthus”; NASD","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/06/3288455/0/en/LBL-047-Prioritized-for-Clinical-Development-in-Sj%C3%B6gren-s-Disease-Systemic-Lupus-Erythematosus-and-Dermatomyositis.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4161","BK4546","DM","SLE","DNTH","TACI","BK4077","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633146924","title":"Super League sets first-quarter 2026 earnings release, hosts results webinar","url":"https://stock-news.laohu8.com/highlight/detail?id=2633146924","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633146924?lang=en_us&edition=fundamental","pubTime":"2026-05-06 04:45","pubTimestamp":1778013905,"startTime":"0","endTime":"0","summary":"Super League to release first-quarter 2026 results before market open May 15, 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nNDL7GSTxT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2T93.GBP","SLE","BK4112","IE00BGHQF748.EUR","IE00B64PRP62.GBP","BK4585","BK4077","IE00BN0W2V16.EUR","IE00BN0W2W23.USD","LU0314104364.USD","SG9999014039.USD","SG9999014021.USD","IE00B3QW5Z07.USD","BK4588","NDAQ","LU2210150020.SGD","LU2210149790.SGD","IE00BKPKM429.USD","LU2095319765.USD","SG9999014005.SGD","SG9999014013.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633251929","title":"Press Release: Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2633251929","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633251929?lang=en_us&edition=fundamental","pubTime":"2026-05-06 04:01","pubTimestamp":1778011260,"startTime":"0","endTime":"0","summary":"Early GO decision reached in CAPTIVATE in March 2026 based on GO criteria of 20 confirmed responders achieved with less than 40 planned participants completing open-label Part A. Claseprubart granted Orphan Drug Designation by FDA for Myasthenia Gravis. Phase 3 registrational trial of claseprubart evaluating 300mg/2mL Q2W and 300mg/2mL Q4W in generalized Myasthenia Gravis  on track to initiate in mid-2026; top-line results anticipated in 2H'28. Phase 2 MoMeNtum trial of claseprubart in Multifocal Motor Neuropathy  ongoing; top-line results on track for Q4'26. Building a rheumatology franchise around DNTH212 with first three priority indications of Sjgren's Disease , Systemic Lupus Erythematosus , and Dermatomyositis . Further strengthened the balance sheet with approximately $719 million in gross proceeds from an underwritten public offering of common stock and pre-funded warrants. Approximately $1.2 billion of cash as of March 31, 2026 provides expected runway into 2030. NEW YORK and ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4546","LENZ","BK4539","AAN","BK4178","BK4139","BK4007","DM","BK4077","BK4161","DNTH","SLE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633254209","title":"INmune Bio and Anthony Nolan Announce Strategic Expansion of CORDStrom™ MSC Platform Collaboration to Target RDEB, Oncology, and Inflammatory Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2633254209","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633254209?lang=en_us&edition=fundamental","pubTime":"2026-05-06 04:00","pubTimestamp":1778011200,"startTime":"0","endTime":"0","summary":"LONDON, UK and BOCA RATON, FL, May  05, 2026 (GLOBE NEWSWIRE) --  INmune Bio Inc. (NASDAQ: INMB) (“INmune Bio”), a clinical-stage biotechnology company, and Anthony Nolan, a pioneering UK-based charit","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/05/3288193/0/en/INmune-Bio-and-Anthony-Nolan-Announce-Strategic-Expansion-of-CORDStrom-MSC-Platform-Collaboration-to-Target-RDEB-Oncology-and-Inflammatory-Diseases.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4150","SLE","BK4139","BK4575","MSC","INMB","BK4077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633425948","title":"Fate Therapeutics Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of FT819","url":"https://stock-news.laohu8.com/highlight/detail?id=2633425948","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633425948?lang=en_us&edition=fundamental","pubTime":"2026-05-05 20:30","pubTimestamp":1777984200,"startTime":"0","endTime":"0","summary":"FDA Chemistry, Manufacturing, and Controls (CMC) Development and Readiness Pilot (CDRP) program supports the acceleration of manufacturing readiness for therapies with expedited clinical development t","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/05/3287697/24675/en/Fate-Therapeutics-Selected-for-U-S-FDA-Chemistry-Manufacturing-and-Controls-Development-and-Readiness-Pilot-Program-to-Support-Manufacturing-Readiness-of-FT819.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMC","IE00BKVL7J92.USD","BK4006","BK4139","IE00B1BXHZ80.USD","LU2746668461.USD","BK4230","LU0971096721.USD","LU2237443465.HKD","CAR","LU0149725797.USD","IE00BHPRN162.USD","SLE","LU2237443622.USD","BK4585","BK4588","BK4022","IE00BFXG1179.USD","LU2237443549.SGD","LU1363072403.SGD","LU0267386448.USD","LU0170899867.USD","LU2237443382.USD","LU2237443895.HKD","LABU","LU2237443978.SGD","LU0882574139.USD","BK4077","LU2746668974.SGD","IE00BZ1G4Q59.USD","FATE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633914063","title":"Climb Bio Hosts Budoprutug R&D Spotlight Event Highlighting Topline Subcutaneous Formulation Data, Broad B-Cell Mediated Disease Opportunity, and Upcoming Data Readouts","url":"https://stock-news.laohu8.com/highlight/detail?id=2633914063","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633914063?lang=en_us&edition=fundamental","pubTime":"2026-05-05 19:00","pubTimestamp":1777978800,"startTime":"0","endTime":"0","summary":"Robust B-cell depletion observed with budoprutug subcutaneous formulation in healthy volunteers, supporting continued development Budoprutug pMN, ITP, and SLE clinical trials enrolling to plan; Fast T","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/05/3287504/0/en/Climb-Bio-Hosts-Budoprutug-R-D-Spotlight-Event-Highlighting-Topline-Subcutaneous-Formulation-Data-Broad-B-Cell-Mediated-Disease-Opportunity-and-Upcoming-Data-Readouts.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ITP","BK4199","BK4077","SLE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633969366","title":"CRISPR Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2633969366","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633969366?lang=en_us&edition=fundamental","pubTime":"2026-05-05 04:30","pubTimestamp":1777926600,"startTime":"0","endTime":"0","summary":"ZUG, Switzerland and BOSTON, May  04, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the first quarter ended March 31, 2026. “The first quarter reflec","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/04/3287176/0/en/CRISPR-Therapeutics-Provides-Business-Update-and-Reports-First-Quarter-2026-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRSP","BK4532","IE00BSNM7G36.USD","BK4022","LU2543165471.USD","LU2264538146.SGD","LU0742534661.SGD","LU2106854487.HKD","LU1064131342.USD","BK4556","BK4520","LU0251142724.SGD","CAR","KSA","LU2237438978.USD","LU1974910355.USD","BK4504","BK4149","FXI","LU2357305700.SGD","BK4516","LU0048573561.USD","LU0942090050.USD","LU1988902786.USD","BK4230","BK4611","CAT","IE00BD6J9T35.USD","UAE","LU1861559042.SGD","SCD","LU1548497426.USD","BK4139","LU0251131958.USD","LU0868494708.USD","BK4199","LU0963586101.USD","LU1861558580.USD","LU0868494617.USD","BK4597","BK4077","SLE","LU1720051017.SGD","LU1917777945.USD","IND","LU2023250504.SGD","LU1720051108.HKD","ITP","BK4585","AGT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632554409","title":"Fate Therapeutics Announces Three Presentations at the 2026 ASGCT Annual Meeting Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2632554409","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632554409?lang=en_us&edition=fundamental","pubTime":"2026-05-04 21:00","pubTimestamp":1777899600,"startTime":"0","endTime":"0","summary":"SAN DIEGO, May  04, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent s","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/04/3286762/24675/en/Fate-Therapeutics-Announces-Three-Presentations-at-the-2026-ASGCT-Annual-Meeting-Highlighting-Off-the-Shelf-CAR-T-cell-Therapy-Pipeline-for-Cancer-and-Autoimmune-Diseases.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4077","FATE","SLE","CAR","BK4230","BK4022","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632324929","title":"Cabaletta Bio reports promising RESET-PV and RESET-SLE data","url":"https://stock-news.laohu8.com/highlight/detail?id=2632324929","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632324929?lang=en_us&edition=fundamental","pubTime":"2026-05-04 18:32","pubTimestamp":1777890762,"startTime":"0","endTime":"0","summary":"Cabaletta Bio ( ($CABA) ) has issued an update. On May 14, 2026, Cabaletta Bio planned to present new clinical and translational data from four ref...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cabaletta-bio-reports-promising-reset-pv-and-reset-sle-data?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cabaletta-bio-reports-promising-reset-pv-and-reset-sle-data?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4077","BK4139","CABA","SLE"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":4,"totalSize":112,"code":"91000000","status":"200"}]}}